Facts and figures

products icon

30 million patients
use our
diabetes care products
 

products icon

We sell our products
in around
170 countries
 

affiliates icon

We have
affiliate offices
in 80 countries

Our products


Main product areas

Diabetes
Obesity
Haemophilia
Growth disorders
Hormone replacement therapy

Our products

 



PERFORMANCE

Annual sales
2019


122,021 million Danish kroner

Q1 total sales
2020


33,875 million Danish kroner

Quarterly announcement

 

Sales by region
Q1 2020


North America Operations

15,579 million Danish kroner


USA: 14,775 million Danish kroner

Canada: 804 million Danish kroner

 

International Operations

18,296 million Danish kroner


Region EMEA: 9,674 million Danish kroner

Region China: 3,813 million Danish kroner

Rest of World: 4,809 million Danish kroner

 

Sales by business segment
Q1 2020


Diabetes and obesity care total

28,591 million Danish kroner

 

Biopharmaceuticals total

5,284 million Danish kroner

 


R&D AT A GLANCE
 

research icon

We invest 11.7%
of net sales
in R&D
 

employee icon

18% of our
global workforce
works within R&D
 

research icon

We have R&D centres
in China, Denmark,
India, UK and US
 


Our research focus



ACCESS TO MEDICINE
 


All people diagnosed with diabetes should receive treatment

Learn more about our access and affordability activities

Graphic: Insulin vials

In 2019, 3 million patients received low-priced human insulin through our Access to Insulin Commitment.

 

Graphic: Children

Our Changing Diabetes in Children® programme has provided treatment to 25,000+ children with type 1 diabetes

 

Graphic: Donations

In 2019, we donated 
86 million Danish kroner
to the World Diabetes Foundation

 


OUR PEOPLE
 

Number of employees

More than 43,100 employees (FTEs as of March 2020)


Business area distribution

18% within research and development

33% in production and production administration

40% in international sales and marketing

9% in administration
 

Novo Nordisk employees angaging

Affiliate distribution
(FTEs as of December 2019)

Approximately 39% of employees are located in Denmark (16,466 FTEs) and 61% in the rest of the world:

Region China (Mainland China, Hong Kong &Taiwan): 5,317 FTEs

Denmark: 16,465 FTEs 

EMEA (Europe excl. HQ, the Middle East and Africa): 11,064 FTEs

Rest of World: 4,100 FTEs

North America (US 5,858 & Canada 354): 6,212 FTEs

(includes Novo Nordisk and NNE employees)

 


PRODUCTION AT A GLANCE
 

affiliates icon

We supply
nearly half
the world's insulin

 

Clean energy icon

Zero
environmental impact is our ambition

 

research icon

Strategic production
sites in Brazil, China,
Denmark, France and
the US
 


HEADQUARTERS & REGIONAL OFFICES
 

Novo Nordisk headquarters, Bagsværd, Denmark

Corporate
headquarters

Bagsværd, Denmark

 

North America
Operations

Plainsboro, NJ, US

 

International
Operations

Zürich, Switzerland

 

Regional
offfices

Beijing (China)
Sao Paolo (Latin America)
Tokyo (Japan & Korea)
Copenhagen (Europe)
Dubai (Africa, Asia, Middle East & Oceania)

 


Novo Nordisk Annual Report 2019